Sano worked with a pioneering biotech company to identify, screen and retain LRRK2:G2019S genetic Parkinson’s Disease (PD) patients for the initial stages of a new treatment development program.
Global prevalence rates of this genetic variation are 1% in sporadic PD and 4% in familial PD.
Download our case study to learn more.
Download Case Study
Parkinson's disease Case Study
Sano worked with a pioneering biotech company to identify, screen and retain LRRK2:G2019S genetic Parkinson’s Disease (PD) patients for the initial stages of a new treatment development program.
Global prevalence rates of this genetic variation are 1% in sporadic PD and 4% in familial PD.
Key Highlights
2x the industry benchmark hit-rate
55% cost savings using at-home DNA testing service vs. site visit
.png)
